Background Adipokines exert pleiotropic actions, including immunoregulatory and matrix degrading effects. They seem to be involved in the pathogenesis of cardiovascular (CV) disease as well as inflammatory rheumatic disease (IRD), and, in theory, they might contribute to the accelerated atherosclerosis in IRD. While leptin increases CV risk, adiponectin may have a cardioprotective effect.
Objectives The aim of this study was to compare serum levels of leptin and adiponectin in coronary artery disease (CAD) patients with and without RA, patients with RA without CAD and healthy controls (HC).
Methods S-leptin and s-adiponectin were measured by ELISA in four groups of patients from the Feiring Heart Biopsy Study: 1) RA patients referred to coronary artery bypass grafting (CABG) (CAD+RA group, n=22); 2) Patients without RA, referred to CABG (CAD non-RA group, n=52); 3) RA patients without CAD (RA non-CAD group, n=17); and 4) HC (n=29).
Results S-adiponectin was significantly lower in CAD+RA than in RA without CAD (Figure 1A). The mean s-leptin was significantly lower in HC than in CAD non-RA, CAD+RA and RA without CAD (Figure 1B). Leptin/adiponectin-ratio was significantly lower in HC than in CAD non-RA and CAD+RA (Figure 1C). In linear regression analyses, CAD was related to lower s-adiponectin levels, and this relationship was independant of age, sex, RA, s-triglycerides, s-HDL and ESR (Table 1). CAD was associated with higher s-leptin and leptin/adiponectin-ratio, and these associations were independent of age, sex and RA (Table 2 and 3). There were no significant associations between s-adiponectin, s-leptin or leptin/adiponectin-ratio and RA disease activity score 28 (DAS28).
Conclusions CAD was related to higher levels of s-leptin and leptin/adiponectin ratio, but to lower levels of s-adiponectin. The relationship between s-adiponectin and CAD was independent of RA, age, sex, triglycerides, HDL and ESR. As for non-RA patients, adiponectin may infer a cardioprotective effect in RA patients that is, at least partly, independent of disease activity.
Disclosure of Interest None declared